Table 1.
Characteristics of study population: Hospitalized COVID-19 patients with IBD, RA, SpA or PsA (exposed group), and hospitalized COVID-19 patients without any of these diagnoses (unexposed group). COVID-19 hospitalizations from March 1 to October 31, 2020.
| Patients with chronic inflammatory diseases (exposed cohort) N = 132 |
Patients without chronic inflammatory diseases (unexposed cohort) N = 2811 |
|
|---|---|---|
| Age (years) at admission | ||
| Median (25–75 percentiles) | 74 (63–80) | 69 (54–80) |
| Patient's age in categories (years), N (%) | ||
| < 19 | 0 (0) | 21 (0.7) |
| 20-39 | 2 (1.5) | 238 (8.4) |
| 40-59 | 22 (16.4) | 718 (25.3) |
| 60-69 | 27 (20.1) | 466 (16.4) |
| 70-79 | 48 (35.8) | 675 (23.8) |
| ≥ 80 | 33 (24.6) | 693 (24.4) |
| Gender, N (%) | ||
| Female | 80 (60.6) | 1227 (43.6) |
| Male | 52 (39.4) | 1584 (56.4) |
| Comorbiditya,N (%) | ||
| 0 | 15 (11.4) | 1341 (47.7) |
| 1-2 | 61 (46.2) | 897 (31.9) |
| ≥3 | 56 (42.4) | 573 (20.4) |
| Diseaseb | ||
| IBD, N (%) | 52(39.4) | |
| RA, N (%) | 69 (52.3) | |
| SpA, N (%) | 3 (2.3) | |
| PsA, N (%) | 12 (9.1) | |
| Categories of medicationc, N (%) | ||
| Thiopurines | 3 (2.3) | 4 (0.1) |
| Methotrexate | 12 (9.1) | 5 (0.2) |
| Systemic corticosteroids | 26 (19.7) | 207 (7.4) |
| Anti-TNF α agents | 8 (6.1) | 5 (0.2) |
a)
Charlson's comorbidity index (CCI) is based on ICD-10 disease history within the last 10 years.
b)
Patients can have more than one disease, hence the sum is larger that the total.
c)
Patients can have used medication in more than one of these categories within six months before the COVID-19 hospitalization.